Abstract
This article is a review of “Long-term effects of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial” by Burn et al. (2011), Lancet, 378, 2081–2087. For another perspective on the Burn et al. article as well as a discussion of challenges faced when interpreting a large prospective trial, please see the related article by Rita Wickham.
